Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$88.7MCash on Hand
5.9mo Cash Runway
Follow KOD by emailGet an email when KOD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KOD, unsubscribe in one click. Privacy
📣 What KOD Says Is Next
fourth quarter of 2026 · “Completion of enrollment in the second pivotal cohort, evaluating 600 patients across the PEAK and PINNACLE studies, is expected in the fourth quarter of 2026, with topline clinical data release anticipated in the second quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
fourth quarter of 2026 · “Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in the fourth quarter of 2026, with topline clinical data release anticipated in the second quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
by year end · KSI-101: “We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies," continued Dr. Perlroth.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Kodiak reported Q3 2026 net loss of $66.2 million, or $1.05 per share, with cash of $88.7 million, and raised $69 million net via its ATM after quarter end. Zenkuda's DAYBREAK Phase 3 met its primary endpoint (p-value 0.0007), and KSI-101 Phase 3 topline data is expected in December 2026. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 20, 2026 ·
Financing Kodiak Sciences filed a shelf registration allowing it to sell common stock, preferred stock, debt, warrants and units in future offerings. It also covers a distribution agreement with J.P. Morgan for up to $350,000,000 of common stock. Nasdaq closing price on October 19, 2026 was $91.35. Form S-3ASR · SEC filing
Sep 28, 2026 ·
Clinical trial Kodiak said Zenkuda (tarcocimab tedromer) met its primary endpoint in the DAYBREAK wet AMD study (p-value 0.0007), with 54% of patients on 6-month dosing, and plans a BLA in 4Q2026. Tabirafusp-ted met its vision primary endpoint (p-value 0.0036). Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 results: net loss of $65.6 million, or $1.05 per share, versus $54.3 million, or $1.03 per share, a year earlier. Cash of $125.9 million is expected to fund operations into 2027. DAYBREAK Phase 3 wet AMD topline data are expected in September 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2027 · Phase 3 · Recruiting · A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE Registry primary completion date, not a results date
Apr 2027 · Phase 3 · Recruiting · A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK Registry primary completion date, not a results date
Aug 2028 · Phase 3 · Recruiting · A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO Registry primary completion date, not a results date
Sep 2026 · Phase 3 · Active Trial · A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)… Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not KOD's own candidates): Aflibercept.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
KOD holds $88.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $45.1M/quarter from operations,
an estimated runway of 5.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:52 · Elevated
Cash runway 9 months +30
Going-concern doubt in the latest 10-Q +15Our financial condition raises substantial doubt about our ability to continue as a going concern.10-Q, Nov 2026
Share count +23% in a year +7
Recent financing filings on SEC EDGAR:
Dec 17, 2025 · Underwritten offering, $160M · 424B5
Share count 65,395,553 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KOD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KOD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.